BiotechTube

Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) + Fulvestrant

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Breast Neoplasms

Conditions

Breast Neoplasms, Neoplasm Metastasis

Trial Timeline

Feb 22, 2021 → Jan 9, 2023

NCT ID
NCT04707196

About Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) + Fulvestrant

Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) + Fulvestrant is a approved stage product being developed by Eli Lilly for Breast Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT04707196. Target conditions include Breast Neoplasms, Neoplasm Metastasis.

What happened to similar drugs?

20 of 20 similar drugs in Breast Neoplasms were approved

Approved (20) Terminated (5) Active (0)
✅arzoxifeneEli LillyApproved
✅Eribulin Injection [Halaven] + Paclitaxel injectionEisaiApproved
✅Eribulin mesylateEisaiApproved
✅Eribulin MesylateEisaiApproved
✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Eli LillyApproved
✅Abemaciclib + Fulvestrant + Standard ChemotherapyEli LillyApproved
✅Abemaciclib + Aromatase Inhibitor + Abemaciclib + FulvestrantEli LillyApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04707196ApprovedCompleted

Competing Products

20 competing products in Breast Neoplasms

See all competitors
ProductCompanyStageHype Score
LymphoseekNavidea BiopharmaceuticalsPhase 3
30
LymphoseekNavidea BiopharmaceuticalsPhase 3
30
ALT-P7 (HM2-MMAE)AlteogenPhase 1
29
Biomarkers blood, urine and microbiota samplesEli LillyPre-clinical
30
gemcitabine + paclitaxel + bevacizumabEli LillyPhase 2
35
Gemcitabine + Adriamycine + PaclitaxelEli LillyPhase 2
35
Abemaciclib + FulvestrantEli LillyPhase 2
27
VS-6766 + Abemaciclib + FulvestrantEli LillyPhase 1/2
39
gemcitabine + vinorelbineEli LillyPhase 2
35
Abemaciclib + Fulvestrant + PlaceboEli LillyPhase 3
44
Azenosertib + Carboplatin + PembrolizumabZentalis PharmaceuticalsPhase 1/2
26
AbemaciclibEli LillyPre-clinical
26
pemetrexed + cyclophosphamide + doxorubicin + docetaxelEli LillyPhase 2
35
arzoxifeneEli LillyApproved
43
BBI-355 + Erlotinib + Futibatinib + BBI-825Boundless BioPhase 1
23
BBI-940 + FulvestrantBoundless BioPhase 1
26
LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + FulvestrantEli LillyPhase 3
47
pemetrexed + gemcitabineEli LillyPhase 2
35
Experimental Arm A: Pemetrexed + Experimental Arm A: Sorafenib + Experimental Arm B: Pemetrexed + Experimental Arm B: SorafenibEli LillyPhase 2
27
pemetrexedEli LillyPhase 2
35